Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012–2018

Antiviral Research

Volumn 164, Issue , 2019, Pages 91-96

  Koszalka, Paulina ^a,b   Tilmanis, Danielle ^a   Roe, Merryn ^a   Vijaykrishna, Dhanasekaran ^a,b,c   Hurt, Aeron C ^a,d  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiviral activity; Baloxavir marboxil; Influenza; Resistance; Susceptibility

Indexed keywords

BALOXAVIR MARBOXIL; SIALIDASE INHIBITOR; ANTIVIRUS AGENT; BALOXAVIR; ENZYME INHIBITOR; OXAZINE DERIVATIVE; PA PROTEIN, INFLUENZA VIRUSES; PYRIDINE DERIVATIVE; RNA DIRECTED RNA POLYMERASE; THIEPIN DERIVATIVE; TRIAZINE DERIVATIVE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; AUSTRALIA; CAMBODIA; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; EC50; FIJI; IN VITRO STUDY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA VIRUS; MALAYSIA; NEW CALEDONIA; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; REVERSE GENETICS; SINGAPORE; SITE DIRECTED MUTAGENESIS; SRI LANKA; THAILAND; VIRUS RECOMBINANT; VIRUS TITRATION; ANTIVIRAL RESISTANCE; DRUG EFFECT; ENZYMOLOGY; IC50; INFLUENZA B VIRUS; MICROBIAL SENSITIVITY TEST; ORTHOMYXOVIRIDAE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; ORTHOMYXOVIRIDAE; OXAZINES; PYRIDINES; RNA REPLICASE; THIEPINS; TRIAZINES; VIRAL PROTEINS;

EID: 85061619800     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2019.02.007     Document Type: Article

References (27)

1. Böttcher, E., et al. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine 27:45 (2009), 6324–6329.
2. de Mello, C.P.P., et al. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system. Eur. J. Pharm. Sci. 111 (2018), 443–449.
3. Dong, G., et al. Adamantane-resistant influenza a viruses in the world (1902–2013): frequency and distribution of M2 gene mutations. PLoS One, 10(3), 2015, e0119115.
4. Escuret, V., et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 41:1 (2008), 25–28.
5. Farrukee, R., et al. Influenza viruses with B/Yamagata-and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility. J. Antimicrob. Chemother. 70:7 (2015), 2004–2012.
6. Gubareva, L.V., et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill., 24(3), 2019, 1800666.
7. Hauge, S.H., et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08. Emerg. Infect. Dis., 15(2), 2009, 155.
8. Hayden, F.G., et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 379:10 (2018), 913–923.
9. Heinonen, S., et al. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin. Infect. Dis. 51:8 (2010), 887–894.
10. Hurt, A.C., et al. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J. Virol. 84:18 (2010), 9427–9438.
11. Ison, Michael G., M, M., Portsmouth, Simon, Yoshida, Yuki, Shishido, Takao, Hayden, Frederick, Uehara, Takeki, Phase 3 trial of baloxavir marboxil in high risk influenza patients (CAPSTONE-2 study). IDweek 2018, 2018.
12. Kawaguchi, N., et al. Evaluation of drug–drug interaction potential between baloxavir marboxil and oseltamivir in healthy subjects. Clin. Drug Investig. 38:11 (2018), 1053–1060.
13. Kawai, N., et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003–2004 and 2004–2005 influenza seasons. Clin. Infect. Dis. 43:4 (2006), 439–444.
14. Koshimichi, H., et al. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin. Drug Investig. 38:12 (2018), 1189–1196.
15. Lackenby, A., et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. Antivir. Res. 157 (2018), 38–46.
16. Matrosovich, M., et al. Overexpression of the α-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:15 (2003), 8418–8425.
17. Matsuzaki, Y., et al. A two-year survey of the oseltamivir-resistant influenza A (H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol. J., 7(1), 2010, 53.
18. Noshi, T., et al. S-033447/S-033188, a novel small molecule inhibitor of cap-dependent endonuclease of influenza A and B virus: in vitro antiviral activity against clinical strains. Open Forum Infectious Diseases, 2016, Oxford University Press.
19. Noshi, T., et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antivir. Res. 160 (2018), 109–117.
20. Omoto, S., et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep., 8(1), 2018, 9633.
21. Singh, S., et al. Clinical benefits with oseltamivir in treating influenza in adult populations. Clin. Drug Investig. 23:9 (2003), 561–569.
22. Sugaya, N., et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 44:2 (2007), 197–202.
23. Sullivan, S.G., et al. Low interim influenza vaccine effectiveness, Australia. Euro Surveill., 22(43), 2017 1 May to 24 September 2017.
24. Takashita, E., et al. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front. Microbiol., 9, 2018, 3026.
25. Thompson, W.W., et al. Estimates of US influenza‐associated deaths made using four different methods. Influenza Other Respir. Viruses 3:1 (2009), 37–49.
26. Tilmanis, D., et al. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 147 (2017), 142–148.
27. Zhang, J.-H., Chung, T.D., Oldenburg, K.R., A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4:2 (1999), 67–73.